

In the Claims:

Please cancel claims 52-68 without prejudice or disclaimer.

Please add new claims 69-78 as follows:

*July 9, 1* 69. (New) A pharmaceutical composition that induces tolerance to an antigen, said toelrogenic composition comprising a non-tumor lymphoid or hematopoietic cell suitable for introduction into an individual and a pharmaceutically acceptable excipient, wherein said cell contains a nucleic acid sequence encoding a fusion protein operably linked to a promoter, said fusion protein comprising (1) an immunoglobulin heavy chain or light chain; and (2) a polypeptide containing at least one epitope of the antigen to which tolerance is desired to be induced; wherein said composition induces tolerance to the antigen in an individual.

*F 4* 70. (New) The pharmaceutical composition of claim 69, wherein said nucleic acid sequence comprises a viral vector.

71. (New) The pharmaceutical composition of claim 70, wherein said viral vector is selected from the group consisting of retroviral vector and baculovirus vector.

72. (New) The pharmaceutical composition of claim 70, wherein there are two or more copies of the nucleic acid sequence encoding said fusion protein operatively linked to said promoter.

73. (New) The pharmaceutical composition of claim 70, wherein the immunoglobulin is an IgG.

*Sub 92*

74. (New) The pharmaceutical composition of claim 70, wherein said fusion protein comprises an N-terminal variable region of said heavy chain and has said polypeptide or portion thereof inserted adjacent to the first framework region of said N-terminal variable region.

75. (New) The pharmaceutical composition of claim 70, wherein the nucleic acid sequence is introduced by transduction.

*F 4*

76. (New) The pharmaceutical composition of claim 70, wherein the cell is syngeneic with the individual.

77. (New) The pharmaceutical composition of claim 70, wherein the cell is a bone marrow cell.

78. (New) The pharmaceutical composition of claim 70, wherein the cell is a B-cell.

---